Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm
Oncodriver genes are usually identified when mutations recur in multiple tumours. Different drivers often converge in the activation or repression of key cancer-relevant pathways. However, as many pathways contain multiple members of the same gene family, individual mutations might be overlooked, as...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23 July 2019
|
| In: |
Oncogene
Year: 2019, Volume: 38, Issue: 38, Pages: 6491-6506 |
| ISSN: | 1476-5594 |
| DOI: | 10.1038/s41388-019-0895-2 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1038/s41388-019-0895-2 Verlag: https://www.nature.com/articles/s41388-019-0895-2 
|
| Author Notes: | Francesco Raimondi, Asuka Inoue, Francois M.N. Kadji, Ni Shuai, Juan-Carlos Gonzalez, Gurdeep Singh, Alicia Alonso de la Vega, Rocio Sotillo, Bernd Fischer, Junken Aoki, J. Silvio Gutkind, Robert B. Russell |
| Summary: | Oncodriver genes are usually identified when mutations recur in multiple tumours. Different drivers often converge in the activation or repression of key cancer-relevant pathways. However, as many pathways contain multiple members of the same gene family, individual mutations might be overlooked, as each family member would necessarily have a lower mutation frequency and thus not identified as significant in any one-gene-at-a-time analysis. Here, we looked for mutated, functional sequence positions in gene families that were mutually exclusive (in patients) with another gene in the same pathway, which identified both known and new candidate oncodrivers. For instance, many inactivating mutations in multiple G-protein (particularly Gi/o) coupled receptors, are mutually exclusive with Gαs oncogenic activating mutations, both of which ultimately enhance cAMP signalling. By integrating transcriptomics and interaction data, we show that the Gs pathway is upregulated in multiple cancer types, even those lacking known GNAS activating mutations. This suggests that cancer cells may develop alternative strategies to activate adenylate cyclase signalling in multiple cancer types. Our study provides a mechanistic interpretation for several rare somatic mutations in multi-gene oncodrivers, and offers possible explanations for known and potential off-label cancer treatments, suggesting new therapeutic opportunities. |
|---|---|
| Item Description: | Gesehen am 21.10.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1476-5594 |
| DOI: | 10.1038/s41388-019-0895-2 |